Literature DB >> 29502286

Biological characterization and pluripotent identification of ovine amniotic fluid stem cells.

Wenhua Pei1, Tengfei Lu1, Kunfu Wang2, Meng Ji1, Shuang Zhang3, Fenghao Chen4, Lu Li5, Xiangchen Li6, Weijun Guan7.   

Abstract

Mesenchymal stem cells derived from amniotic fluid have become one of the most potential stem cell source for cell-based therapy for the reason they can be harvested at low cost and without ethical problems. Here, we obtained amniotic fluid stem cells (AFSCs) from ovine amniotic fluid and studied the expansion capacity, cell markers expression, karyotype, and multilineage differentiation ability. In our work, AFSCs were subcultured to passage 62. The cell markers, CD29, CD44, CD73 and OCT4 which analyzed by RT-PCR were positive; CD44, CD73, CD90, CD105, NANOG, OCT4 analyzed by immunofluorescence and flow cytometry were also positive. The growth curves of different passages were all typically sigmoidal. The different passages cells took on a normal karyotype. In addition, AFSCs were successfully induced to differentiate into adipocytes, osteoblasts and chondrocytes. The results suggested that the AFSCs isolated from ovine maintained normal biological characteristics and their multilineage differentiation potential provides many potential applications in cell-based therapies and tissue engineering.

Entities:  

Keywords:  Amniotic fluid; Differentiation; Ovine; Stem cell

Year:  2018        PMID: 29502286      PMCID: PMC6021295          DOI: 10.1007/s10616-017-0115-2

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  40 in total

Review 1.  Amnion-derived pluripotent/multipotent stem cells.

Authors:  Toshio Miki; Stephen C Strom
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

2.  Amniotic fluid cells are more efficiently reprogrammed to pluripotency than adult cells.

Authors:  Elisa Galende; Ioannis Karakikes; Lisa Edelmann; Robert J Desnick; Thomas Kerenyi; Georges Khoueiry; James Lafferty; Joseph T McGinn; Michael Brodman; Valentin Fuster; Roger J Hajjar; Katalin Polgar
Journal:  Cell Reprogram       Date:  2010-04       Impact factor: 1.987

Review 3.  Mesenchymal stem cells: characteristics and clinical applications.

Authors:  Sylwia Bobis; Danuta Jarocha; Marcin Majka
Journal:  Folia Histochem Cytobiol       Date:  2006       Impact factor: 1.698

4.  Amniotic fluid stem cells are cardioprotective following acute myocardial infarction.

Authors:  Sveva Bollini; King K Cheung; Johannes Riegler; Xuebin Dong; Nicola Smart; Marco Ghionzoli; Stavros P Loukogeorgakis; Panagiotis Maghsoudlou; Karina N Dubé; Paul R Riley; Mark F Lythgoe; Paolo De Coppi
Journal:  Stem Cells Dev       Date:  2011-07-08       Impact factor: 3.272

Review 5.  Potential antitumor therapeutic strategies of human amniotic membrane and amniotic fluid-derived stem cells.

Authors:  N-H Kang; K-A Hwang; S U Kim; Y-B Kim; S-H Hyun; E-B Jeung; K-C Choi
Journal:  Cancer Gene Ther       Date:  2012-06-01       Impact factor: 5.987

Review 6.  Mesenchymal stem cells as therapeutics.

Authors:  Biju Parekkadan; Jack M Milwid
Journal:  Annu Rev Biomed Eng       Date:  2010-08-15       Impact factor: 9.590

7.  Stem cells derived from amniotic fluid: new potentials in regenerative medicine.

Authors:  Mara Cananzi; Anthony Atala; Paolo De Coppi
Journal:  Reprod Biomed Online       Date:  2009       Impact factor: 3.828

8.  Identification of mesenchymal progenitor cells in normal and osteoarthritic human articular cartilage.

Authors:  Saifeddin Alsalameh; Rayya Amin; Takefumi Gemba; Martin Lotz
Journal:  Arthritis Rheum       Date:  2004-05

9.  Immune regulatory properties of CD117(pos) amniotic fluid stem cells vary according to gestational age.

Authors:  Mariano Di Trapani; Giulio Bassi; Emanuela Fontana; Luca Giacomello; Michela Pozzobon; Pascale V Guillot; Paolo De Coppi; Mauro Krampera
Journal:  Stem Cells Dev       Date:  2015-01-01       Impact factor: 3.272

10.  A novel method to derive amniotic fluid stem cells for therapeutic purposes.

Authors:  Tatsanee Phermthai; Yuparat Odglun; Suphakde Julavijitphong; Vitaya Titapant; Prakong Chuenwattana; Chanchai Vantanasiri; Kovit Pattanapanyasat
Journal:  BMC Cell Biol       Date:  2010-10-19       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.